Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Adverse effects in childhood lead to immune impairment later in life

The emotional pains we suffer in childhood can lead to weakened immune systems later in life, according to a new study.Based on this new research, the amount of this immune impairment even enhances that caused by the stress of caregiving later in life."What happens in childhood really matters when it comes to your immune response in the latter part of your life," explained Janice Kiecolt-Glaser, professor of psychology and psychiatry at Ohio State University. She explained her work at the annual meeting of the American Psychological Association in San Diego.

16 Aug 2010

Obesity diabetes link found

Melbourne researchers from the Walter and Eliza Hall Institute have found that inflammatory cells in fat tissue cause the body to become resistant to the effects of insulin – a common precursor to type II diabetes.

16 Aug 2010

AHRQ selects Outcome Sciences to study effects of different treatments for open angle glaucoma

Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.

13 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

Intellect Neurosciences receives patent for insulin sensitizer drugs

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that its Chairman & CEO, Dr. Daniel Chain, was granted a patent by the European Patent and Trademark Office related to the use of insulin sensitizers for the prevention and treatment of memory loss and dementia. Insulin sensitizer drugs include Rosiglitazone and Pioglitazone, which have been approved for the treatment of type II diabetes mellitus.

12 Aug 2010

Depomed announces SPA agreement with FDA for Serada Phase 3 trial for menopausal hot flashes

Depomed, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design and analysis of Breeze 3, a Phase 3 trial evaluating Serada® (extended release gabapentin tablets) for menopausal hot flashes.

11 Aug 2010

Repros receives US patent for Androxal

Repros Therapeutics Inc. today announced the US Patent and Trademark office has issued U.S. Patent No. 7,759,360 for Androxal, the Company's lead program for the treatment of low testosterone in men. This patent specifically claims methods and materials for the treatment of testosterone deficiency in men with secondary hypogonadism. Repros has over 35 issued or pending US and European patents involving Androxal.

11 Aug 2010

Researchers receive $1M grant to train Native American communities improve their health

UC Davis School of Medicine researchers will train Native American communities in Northern California to develop and implement culturally appropriate interventions to improve their health by decreasing obesity and type-2 diabetes, through a $1 million research grant from the National Institute of Diabetes and Kidney Diseases of the National Institutes of Health.

11 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Scientists suggest daily intake of vitamin D helps to reduce disease frequency

Anthony Norman, a leading international expert in vitamin D, proposes worldwide policy changes regarding people's vitamin D daily intake amount in order to maximize the vitamin's contribution to reducing the frequency of many diseases, including childhood rickets, adult osteomalacia, cancer, autoimmune type-1 diabetes, hypertension, cardiovascular disease, obesity and muscle weakness.

10 Aug 2010

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics Inc. today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Lexicon Pharmaceuticals updates key progress in clinical pipeline

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated the progress of its drug development programs and reported financial results for the three and six months ended June 30, 2010.

9 Aug 2010

Researchers examine differences in eating habits of African Americans

Researchers looking for differences in eating habits of African Americans based on whether or not they had Type 2 diabetes uncovered an unexpected result: No matter what the blood sugar level was, the dietary intakes were pretty much the same.

7 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

Osiris Therapeutics reports second-quarter net income of $1.7M against loss last year

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular and orthopedic areas, announced today its results for the second quarter of fiscal 2010.

7 Aug 2010

Tufts University faculty debunks common dental myths

Brushing, flossing, and twice-yearly dental check-ups are standard for oral health care, but there are more health benefits to taking care of your pearly whites than most of us know. In a review article, a faculty member at Tufts University School of Dental Medicine (TUSDM) debunks common dental myths and outlines how diet and nutrition affects oral health in children, teenagers, expectant mothers, adults and elders.

7 Aug 2010